BioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical Conditions

BioLamina and collaborators have partnered with Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, allowing Novo Nordisk to develop novel stem cell based therapies based on Biolaminins, human recombinant laminin cell culture matrices, developed and produced by BioLamina.

Novo Nordisk have announced today that they are increasing their commitment to cell therapies, including areas outside of diabetes. The three cell therapy projects they have licensed are all based on BioLamina technology. These projects aim to treat Parkinson’s disease, heart failure and loss of vision, all severe chronic conditions.

Malin Parmar’s research group at Lund University and Karl Tryggvason’s research group at Duke-NUS in Singapore have developed potential cell therapies based on BioLamina’s unique Biolaminin matrices. Both groups have signed research and potential licensing agreements with Novo Nordisk with the aim to develop these projects further together with Novo Nordisk, enabling a translation of cell therapy pre-clinical studies, to clinical trials and eventually towards patient treatments.

The timing for these licensing agreements coincides well with the launch of BioLamina’s first cell therapy grade product a couple of weeks ago, assuring cell therapy developers worldwide that Biolamina’s products can be used all the way from the bench to bedside. There is an ongoing trend that researchers using embryonic stem cell or induced pluripotent based protocols want to use BioLamina products in their product development to make their processes more robust and reproducible.

“There is a high demand for BioLamina’s products in the development of safe and robust cell-based therapies,” says Kristian Tryggvason, CEO for BioLamina, and continues “It is really intriguing to see how Biolaminins are being part of building new therapies and can help contribute treating many people in the future.”